Al-Kindy College Medical Journal (KCMJ)

Editorial

The Impact of Personalized Medicine on Enhancing Quality of Life in Chronic Diseases Management

Ekhlas Khalid Hameed[1], Laith Thamer Al-Ameri[1]*, Ziad Dulaimi[2], May Yousif Wahdan[3], Rand Almomen[4]

1 Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq
2 Madinat Zayed Hospital, Aldhafra, Abu Dhabi, UAE
3 Capio care center Hjortmossen, Sweden
4 Department of Neurological Surgery, University of California, San Francisco, USA
* Corresponding author's email: laiththamer@kmc.uobaghdad.edu.iq

Article history:
Received 1 May 2025
Accepted 15 June 2025
Available online 1 August 2025

https://doi.org/10.47723/83sgpc97

Keywords: Personalized Medicine, Ethics, Pharmacogenomics, Artificial Intelligence, Digital Health

ABSTRACT

Personalized Medicine represents a revolution in healthcare practice, focusing on tailoring different therapies to be precise for a specific individual; this is aided by exploring the number of genetic predispositions and lifestyle choices that fit each individual. In this article, the authors utilize and gather recent literature and opinions to discuss the impact of personalized medicine on chronic disease management and patient quality of life with additional attention paid to deal with limitations and possible ethical issues. Chronic diseases such as Hypertension, Diabetes, and chronic kidney diseases adversely affect multiple health indicators, including Quality of Life (QoL) and well-being. This will have additional impacts on physical and mental health that require further mitigations and to deal with more ongoing mental health. Personalized medicine is a revolutionary step that could be used to manage chronic disease by improving patients' QoL through tailored treatments. However, it is crucial to handle equity, ethics, and the limitations in infrastructure issues.

Introduction

Personalized Medicine represents a transforming period in health practice, making a shift in disease management from the traditional to a precise and tailored approach that fits each individual [1-2].

Chronic diseases, such as hypertension, diabetes, and chronic renal diseases, have a negative impact on a variety of health indices, including quality of life and overall well-being. Additionally, there will be effects on both physical and mental health, which will necessitate further preventative measures and the management of more ongoing mental health issues [3-5].

Modulating Effects on Chronic Disease Management

In the context of chronic diseases, Personal Medicine addresses individual differences in responding to therapies; this is addressed through the customization of treatment plans to fit each patient separately.

Designed Interventions: By utilizing genomic information, biomarkers related to a specific condition can be used to predict disease progression and outcome. For example, the Presence of the apolipoprotein E (APOE) genotype, including three alleles (e2, e3, e4), is linked to a higher risk of developing dementia and cardiovascular events; additionally, e4 alleles are linked to higher low-density lipoprotein cholesterol levels resulting in high cardiovascular events, tailoring medicine could be beneficial to target these specific patients. Another example, Tirzepatide, a Dual-Acting Insulinotropic Polypeptide, may be adjusted for specific patients with obesity and Type 2 Diabetes Miletus by using different doses tailored

for each patient with the possibility for future trials for more promising Tirzepatide and other antidiabetic drugs combinations [6-8].

Proactive Care: Personalized medicine enables healthcare to transition from reactive to proactive approaches. Wearable devices combined with artificial intelligence enable early disease exacerbation detection, which leads to prompt medical interventions. Proactive methods enable patients to manage their health independently, which leads to better QoL.

Pharmacogenomics (Medication Optimization): Treatment acts differently through different gene expressions influencing drug metabolism; therefore, optimal drug selection and dosing could be adjusted. For example, trastuzumab could be used for patients with breast cancer showing overexpression of Human epidermal growth factor receptor-2 (HER2), a protein that promotes malignant cell growth. Additionally, recent evidence shows a relation between HER2 and poor prognosis of gastric malignancy. All these will aid in tailoring drug selection toward each specific group of patients [9].

Improving Quality of Life: A Focus on Patient-Centered Approaches

QoL includes aspects of well-being, emotional, and social components that contribute to overall life satisfaction; the influence on these domains is complex and involves a wide range of experiences [3].

Physical Well-Being: Improving symptom management and eliminating side effects enhance physical functioning. Additionally, personalized insulin treatments and ongoing glucose monitoring in customized diabetic care plans to improve glycemic control and lower complications.

Emotional Resilience: Several negative consequences associated with chronic illnesses can cause psychological distress. Personalized medicine will help patients feel confident and reassured by offering individualized, evidence-based treatment plans.

Social Engagement: Improved health results empower patients to engage in essential social activities, reducing feelings of isolation often associated with long-term illnesses.

Limits and Ethical Concerns

Although promising, the integration of personalized medicine presents major ethical issues [10-11].

Equity in Access: Different therapies and instruments used to implement Personalized Medicine may be expensive and make it difficult for many individuals to access them. Authorities should act to equal healthcare services to individuals and minimize variations in accessibility [12].

Data Privacy and Ethics: As the aspect of personalized medicine deals with genetic and health data related to each patient, ethical issues raised concerning data security which need to be addressed correctly.

Healthcare Infrastructure: To be implemented, personalized medicine requires investment in genomic databases, bioinformatics, and clinical training. However, limited funds may make further improvements in this field difficult [10,13].

Future Perspectives

The integration of artificial intelligence with recent advancements in genomics and digital health has the potential to improve the outcomes of patients with chronic diseases enhancing individuals' quality of life. The Human Genome Project promises to demonstrate the potential for global information exchange to accelerate progress. Furthermore, patient education and empowerment will be crucial. Involving patients as active partners in their care promotes collaborative decision-making and enhances compliance with individualized treatment programs.

Conclusion

Personalized medicine is set to revolutionize chronic disease management by improving patients' QoL through tailored treatments. Nonetheless, handling issues involving equity, ethics, and infrastructure is crucial for its wide application. By synchronizing technology with diversity, personalized medicine can realize its transformational promise in global healthcare.

Funding

This research is funded by Al-Kindy College of Medicine, University of Baghdad.

Conflict of Interest

Authors declare no conflict of interest.

ORCID

Ekhlas Hameed 0000-0002-0068-3329
Laith Al-Ameri 0000-0002-5863-1564
Rand Almomen 0000-0002-6133-8115

References

[1] Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. Fertil Steril. 2018 Jun;109(6):952-963. https://doi.org/10.1016/j.fertnstert.2018.05.006

[2] Molla G, Bitew M. Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines. 2024 Nov 30;12(12):2750. https://doi.org/10.3390/biomedicines12122750

[3] Kuriakose S. Global Health: Issues and Challenges. Modern Medicine. 2020;27(1):1-3. https://doi.org/10.31689/rmm.2020.27.1.1

[4] Fernandes JB, Teixeira F, Godinho C. Personalized Care and Treatment Compliance in Chronic Conditions. J Pers Med. 2022 May 1;12(5):737. https://doi.org/10.3390/jpm12050737

[5] Hassan MA, Noaman NG. Epidemiological Study of Non-communicable Diseases Among Patients Attending Nutritional Clinic in Baquba Teaching Hospital. Diyala Journal of Medicine. 2020;19(2):6-12. https://doi.org/10.26505/DJM.19025220122

[6] Haan MN, Mayeda ER. Apolipoprotein E Genotype and Cardiovascular Diseases in the Elderly. Curr Cardiovasc Risk Rep. 2010 Sep;4(5):361-368. https://doi.org/10.1007/s12170-010-0118-4

[7] Al-Ameri LT, Hameed EK, Dulaimi Z, Abdalgbar A, Wahdan MY, Al Joboory A, et al. A Revolutionary Road Map for Obesity Management and Beyond: Tirzepatide as a Dual-Acting Insulinotropic Polypeptide. Al-Kindy Col. Med. J.2024;20(3):158-162. https://doi.org/10.47723/hesy7z38

[8] Ibrahim KS, Hayder ZS, Ahmed AH. Determination of some hematological profiles, inflammatory markers, and their relation with insulin resistance in anemic Type 2 diabetes mellitus patients. Diyala Journal of Medicine. 2022;22(1):130-140 https://doi:10.26505/DJM.22016251103

[9] Lei YY, Huang JY, Zhao QR, Jiang N, Xu HM, Wang ZN, Li HQ, Zhang SB, Sun Z. The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature. World J Surg Oncol. 2017 Mar 21;15(1):68. https://doi.org/10.1186/s12957-017-1132-5

[10] Erdmann, A., Rehmann-Sutter, C. & Bozzaro, C. Patients' and professionals' views related to ethical issues in precision medicine: a mixed research synthesis. BMC Med Ethics 22, 116 (2021). https://doi.org/10.1186/s12910-021-00682-8

[11] Maeckelberghe E, Zdunek K, Marceglia S, Farsides B, Rigby M. The ethical challenges of personalized digital health. Frontiers in medicine. 2023 Jun 19;10:1123863. http://dx.doi.org/10.3389/fmed.2023.1123863

[12] LaftaR. Health System in Iraq Post 2003 War. AL-Kindy College Medical Journal. 2023; 19(3):5–11. https://doi.org/10.47723/kcmj.v19i3.1040

[13] Al_hussaniy HA. Medical Scientific Research Challenges in Iraq. Med. Pharm. J. 2023;2(1):1-3. https://doi.org/10.55940/medphar202228

To cite this article: Hameed EK, Al-Ameri LT, Dulaimi Z, Almomen R. The Impact of Personalized Medicine on Enhancing Quality of Life in Chronic Diseases Management. Al-Kindy Col. Med. J. 2025;21(2):86-88. https://doi.org/10.47723/83sgpc97